Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie Pasritamigu s Docetaxelem versus Docetaxel u účastníků s metastazujícím kastračně rezistentním karcinomem prostaty (KLK2-PASenger)

2. listopadu 2026 aktualizováno: Janssen Research & Development, LLC

Fáze 3 randomizované, otevřené studie pasritamigu (JNJ-78278343), T-buňkami řízeného léčiva cíleného na lidský kallikrein 2, s docetaxelem versus docetaxel u metastatického kastračně rezistentního karcinomu prostaty

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

800

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Heidelberg, Austrálie, 3084
        • Nábor
        • Warringal Private Hospital
      • Kurralta Park, Austrálie, 5037
        • Nábor
        • Icon Cancer Centre Kurralta Park
      • Melbourne, Austrálie, 3000
        • Nábor
        • Peter MacCallum Cancer Centre
      • Wahroonga, Austrálie, 2076
        • Nábor
        • Sydney Adventist Hospital
      • Woolloongabba, Austrálie, 4102
        • Nábor
        • Princess Alexandra Hospital
      • Aalst, Belgie, 9300
        • Nábor
        • AZORG campus Aalst Moorselbaan
      • Antwerp, Belgie, 2610
        • Nábor
        • ZAS Augustinus
      • Ghent, Belgie, 9000
        • Nábor
        • AZ Maria Middelares
      • La Louvière, Belgie, 7100
        • Nábor
        • Chu Helora Hospital La Louviere Site Jolimont
      • Liège, Belgie, 4000
        • Nábor
        • CHC MontLegia
      • Bauru, Brazílie, 17033-495
        • Nábor
        • NAIC Nair Antunes Instituto do Cancer
      • Natal, Brazílie, 59062 000
        • Nábor
        • Liga Norte Riograndense Contra O Cancer
      • Santa Cruz do Sul, Brazílie, 96835-100
        • Nábor
        • Hospital Ana Nery Santa Cruz do Sul
      • Santo André, Brazílie, 09060 870
        • Nábor
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • São Paulo, Brazílie, 01243 020
        • Nábor
        • Hospital Samaritano de Sao Paulo
      • Bordeaux, Francie, 33076
        • Nábor
        • Institut Bergonie
      • Clermont-Ferrand, Francie, 63011
        • Nábor
        • Centre Jean Perrin
      • Lille, Francie, 59000
        • Nábor
        • Centre Oscar Lambret
      • Lyon, Francie, 69008
        • Nábor
        • Centre Leon Berard
      • Nîmes, Francie, 30900
        • Nábor
        • Groupe Hospitalo-Universitaire Carémeau
      • Paris, Francie, 75908
        • Nábor
        • Hopital Europeen Georges-Pompidou
      • Rennes, Francie, 35062
        • Nábor
        • Centre Eugene Marquis
      • Villejuif, Francie, 94800
        • Nábor
        • Gustave Roussy
      • Florence, Itálie, 50134
        • Nábor
        • Azienda Ospedaliero Universitaria Careggi
      • Localita La Schiana Pozzuoli, Itálie, 80078
        • Nábor
        • ASL Napoli 2 Nord-SM delle Grazie Hospital
      • Milan, Itálie, 20141
        • Nábor
        • Istituto Europeo di Oncologia
      • Milan, Itálie, 20132
        • Nábor
        • IRCCS Ospedale San Raffaele
      • Roma, Itálie, 00144
        • Nábor
        • Istituto Nazionale Tumori Regina Elena
      • Torino, Itálie, 10126
        • Nábor
        • Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
      • Bunkyō City, Japonsko, 113 8431
        • Nábor
        • Juntendo University Hospital
      • Hirakata, Japonsko, 573-1191
        • Nábor
        • Kansai Medical University Hospital
      • Kanazawa, Japonsko, 920 8641
        • Nábor
        • Kanazawa University Hospital
      • Kobe, Japonsko, 650 0017
        • Nábor
        • Kobe University Hospital
      • Sagamihara, Japonsko, 252-0375
        • Nábor
        • Kitasato University Hospital
      • Sunto Gun, Japonsko, 411 8777
        • Nábor
        • Shizuoka Cancer Center
      • Yokohama, Japonsko, 232 0024
        • Nábor
        • Yokohama City University Medical Center
      • Goyang-si, Jižní Korea, 10408
        • Nábor
        • National Cancer Center
      • Seoul, Jižní Korea, 05505
        • Nábor
        • Asan Medical Center
      • Seoul, Jižní Korea, 06351
        • Nábor
        • Samsung Medical Center
      • Seoul, Jižní Korea, 03722
        • Nábor
        • Severance Hospital Yonsei University Health System
      • Seoul, Jižní Korea, 06591
        • Nábor
        • The Catholic University of Korea Seoul St Marys Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z4E6
        • Nábor
        • British Columbia Cancer Agency
      • Victoria, British Columbia, Kanada, V8R 6V5
        • Nábor
        • British Columbia Cancer Agency Vancouver Island Centre
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Nábor
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Kanada, M5G 2C4
        • Nábor
        • Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Kanada, H2X 0A9
        • Nábor
        • Centre de Recherche du CHUM
      • Québec, Quebec, Kanada, G1R 2J6
        • Nábor
        • CHU de Quebec Universite Laval
      • Kota Kinabalu, Malajsie, 88996
        • Nábor
        • Hospital Wanita dan Kanak-Kanak Sabah
      • Kuala Lumpur, Malajsie, 59100
        • Nábor
        • University Malaya Medical Centre
      • Kuala Lumpur, Malajsie, 50586
        • Nábor
        • Hospital Kuala Lumpur
      • Kuala Lumpur, Malajsie, 59100
        • Nábor
        • Pantai Hospital Kuala Lumpur
      • Kuching, Malajsie, 93586
        • Nábor
        • Hospital Umum Sarawak
      • Dresden, Německo, 01307
        • Nábor
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Duisburg, Německo, 47169
        • Nábor
        • Urologicum Duisburg
      • Essen, Německo, 45147
        • Nábor
        • Universitaetsklinikum Essen
      • Hamburg, Německo, 20246
        • Nábor
        • Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
      • München, Německo, 81675
        • Nábor
        • Klinikum rechts der Isar an der Technischen Universitat Munchen
      • Nürtingen, Německo, 72622
        • Nábor
        • Studienpraxis Urologie Drs. Feyerabend
      • San Juan, Portoriko, 935
        • Nábor
        • Pan American Center for Oncology Trials LLC
      • Cardiff, Spojené království, CF14 2TL
        • Nábor
        • Velindre Cancer Centre
      • Glasgow, Spojené království, G12 0YN
        • Nábor
        • Beatson West Of Scotland Cancer Centre
      • London, Spojené království, EC1A 7BE
        • Nábor
        • St Bartholomews Hospital
      • London, Spojené království, SW3 6JJ
        • Nábor
        • The Royal Marsden NHS Trust
      • Newcastle upon Tyne, Spojené království, NE7 7DN
        • Nábor
        • The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
      • Preston, Spojené království, PR2 9HT
        • Nábor
        • Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
      • Sutton, Spojené království, SM2 5PT
        • Nábor
        • Royal Marsden Hospital
    • Arizona
      • Chandler, Arizona, Spojené státy, 85225
        • Nábor
        • Arizona Clinical Trials
    • Arkansas
      • Little Rock, Arkansas, Spojené státy, 72211
        • Nábor
        • Arkansas Urology
      • Springdale, Arkansas, Spojené státy, 72762
        • Nábor
        • Highlands Oncology Group
    • California
      • Fountain Valley, California, Spojené státy, 92708
        • Nábor
        • MemorialCare Orange Coast Medical Center
      • La Jolla, California, Spojené státy, 92037
        • Nábor
        • University Of California San Diego
      • Los Alamitos, California, Spojené státy, 90720
        • Nábor
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Spojené státy, 90033
        • Nábor
        • USC Norris Comprehensive Cancer Center
      • Los Angeles, California, Spojené státy, 90095
        • Nábor
        • Ronald Reagan UCLA Medical Center
      • Los Angeles, California, Spojené státy, 90067
        • Nábor
        • Valkyrie Clinical Trials
      • Riverside, California, Spojené státy, 92505
        • Nábor
        • Kaiser Permanente Southern California
      • San Diego, California, Spojené státy, 92123
        • Nábor
        • Sharp Center for Research
      • Santa Monica, California, Spojené státy, 90404
        • Nábor
        • Providence Saint John s Health Center
    • Colorado
      • Aurora, Colorado, Spojené státy, 80012
        • Nábor
        • Rocky Mountain Cancer Centers
      • Denver, Colorado, Spojené státy, 80210
        • Nábor
        • AdventHealth Porter Oncology Research
      • Edwards, Colorado, Spojené státy, 81632
        • Nábor
        • Vail Health Shaw Cancer Center
      • Grand Junction, Colorado, Spojené státy, 81505
        • Nábor
        • Grand Valley Oncology
      • Lakewood, Colorado, Spojené státy, 80228
        • Nábor
        • Colorado Clinical Research
    • Florida
      • Orlando, Florida, Spojené státy, 32803
        • Nábor
        • AdventHealth Orlando
      • Pembroke Pines, Florida, Spojené státy, 33026
        • Nábor
        • Memorial Cancer Institute
      • Sarasota, Florida, Spojené státy, 34232
        • Nábor
        • Florida Cancer Specialists
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30322
        • Nábor
        • Winship Cancer Institute Emory University
    • Illinois
      • Lisle, Illinois, Spojené státy, 60532
        • Nábor
        • Duly Health and Care
    • Kansas
      • Wichita, Kansas, Spojené státy, 67214
        • Nábor
        • Cancer Center of Kansas Heritage Plaza Medical Building
    • Kentucky
      • Edgewood, Kentucky, Spojené státy, 41017
        • Nábor
        • St Elizabeth Healthcare
      • Louisville, Kentucky, Spojené státy, 40207
        • Nábor
        • Norton Cancer Institute
    • Louisiana
      • Metairie, Louisiana, Spojené státy, 70006
        • Nábor
        • East Jefferson General Hospital
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Nábor
        • Johns Hopkins Hospital
      • Baltimore, Maryland, Spojené státy, 21201
        • Nábor
        • University of Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Nábor
        • Johns Hopkins Medical Institutions
      • Bethesda, Maryland, Spojené státy, 20817
        • Nábor
        • Center for Cancer and Blood Disorders
      • Towson, Maryland, Spojené státy, 21204
        • Nábor
        • Chesapeake Urology Research Associates
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02114
        • Nábor
        • Massachusetts General
    • Michigan
      • Sterling Heights, Michigan, Spojené státy, 48314
        • Nábor
        • Profound Research LLC at Cancer and Leukemia Center
    • Minnesota
      • Saint Louis Park, Minnesota, Spojené státy, 55426
        • Nábor
        • HealthPartners Frauenshuh Cancer Center CRC West
      • Saint Paul, Minnesota, Spojené státy, 55101
        • Nábor
        • HealthPartners Cancer Center at Regions Hospital CRC East
    • Mississippi
      • Jackson, Mississippi, Spojené státy, 39216
        • Nábor
        • University of Mississippi Medical Center
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Nábor
        • Washington University
    • Nebraska
      • Lincoln, Nebraska, Spojené státy, 68506
        • Nábor
        • NHO Revive Research Institute, LLC
    • New Jersey
      • Camden, New Jersey, Spojené státy, 08103
        • Nábor
        • Cooper Health System MD Anderson Cancer Center at Cooper
      • East Brunswick, New Jersey, Spojené státy, 08816
        • Nábor
        • Astera Cancer Care
      • New Brunswick, New Jersey, Spojené státy, 08901
        • Nábor
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Mineola, New York, Spojené státy, 11501
        • Nábor
        • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
      • New York, New York, Spojené státy, 10016
        • Nábor
        • NYU Langone Health Laura and Isaac Perlmutter Cancer Center
      • The Bronx, New York, Spojené státy, 10461
        • Nábor
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27710
        • Nábor
        • Duke University Medical Center
    • Ohio
      • Canton, Ohio, Spojené státy, 44718
        • Nábor
        • Gabrail Cancer Center
      • Cincinnati, Ohio, Spojené státy, 45219
        • Nábor
        • University of Cincinnati
      • Cleveland, Ohio, Spojené státy, 44109
        • Nábor
        • Metrohealth Medical Center
    • Oregon
      • Springfield, Oregon, Spojené státy, 97477
        • Nábor
        • Oregon Urology Institute
    • Pennsylvania
      • Allentown, Pennsylvania, Spojené státy, 18103
        • Nábor
        • Lehigh Valley Hospital
      • Bala-Cynwyd, Pennsylvania, Spojené státy, 19004
        • Nábor
        • MidLantic Urology
      • Hershey, Pennsylvania, Spojené státy, 17033
        • Nábor
        • Penn State Milton S. Hershey Medical Center
      • Pittsburgh, Pennsylvania, Spojené státy, 15232
        • Nábor
        • University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    • South Carolina
      • Myrtle Beach, South Carolina, Spojené státy, 29572
        • Nábor
        • Carolina Urologic Research Center
    • South Dakota
      • Sioux Falls, South Dakota, Spojené státy, 57105
        • Nábor
        • Avera Medical Group
      • Watertown, South Dakota, Spojené státy, 57201
        • Nábor
        • Prairie Lakes Health Care System
    • Tennessee
      • Knoxville, Tennessee, Spojené státy, 37909
        • Nábor
        • Tennessee Cancer Specialists
    • Texas
      • Austin, Texas, Spojené státy, 78731
        • Nábor
        • Texas Oncology
      • Dallas, Texas, Spojené státy, 75390
        • Nábor
        • UT Southwestern Medical Center
      • Houston, Texas, Spojené státy, 77027
        • Nábor
        • Houston Metro Urology
      • Sugar Land, Texas, Spojené státy, 77479
        • Nábor
        • Texas Oncology 1
      • The Woodlands, Texas, Spojené státy, 77380
        • Nábor
        • Renovatio Clinical
    • Virginia
      • Fairfax, Virginia, Spojené státy, 22031
        • Nábor
        • Virginia Cancer Specialists
    • Washington
      • Seattle, Washington, Spojené státy, 98109
        • Nábor
        • Fred Hutchinson Cancer Research Center
      • Seattle, Washington, Spojené státy, 98109
        • Nábor
        • Fred Hutch Cancer Center Sloan Clinic 2
      • Taichung, Tchaj-wan, 435
        • Nábor
        • Tungs' Taichung MetroHarbor Hospital
      • Taichung, Tchaj-wan, 404
        • Nábor
        • China Medical University Hospital
      • Taichung, Tchaj-wan, 407219
        • Nábor
        • Taichung Veterans General Hospital
      • Tainan, Tchaj-wan, 704
        • Nábor
        • National Cheng Kung University Hospital
      • Taoyuan, Tchaj-wan, 333
        • Nábor
        • Linkou Chang Gung Memorial Hospital
      • Adana, Turecko (Türkiye), 01170
        • Nábor
        • Adana City Hospital
      • Ankara, Turecko (Türkiye), 06010
        • Nábor
        • Gulhane Training and Research Hospital
      • Ankara, Turecko (Türkiye), 06100
        • Nábor
        • Ankara University Medical Faculty
      • Istanbul, Turecko (Türkiye), 34096
        • Nábor
        • Istanbul University Cerrahpasa tip Fakultesi
      • Istanbul, Turecko (Türkiye), 34147
        • Nábor
        • Koc Universitesi Hastanesi
      • Izmir, Turecko (Türkiye), 35170
        • Nábor
        • Medicana International Izmir
      • Beijing, Čína, 100142
        • Nábor
        • Beijing Cancer Hospital
      • Beijing, Čína, 100034
        • Nábor
        • Peking University First Hospital
      • Beijing, Čína, 101100
        • Nábor
        • Beijing Luhe Hospital, Capital Medical University
      • Chengdu, Čína, 610014
        • Nábor
        • The Third People's Hospital of Chengdu
      • Chengdu, Čína, 610041
        • Nábor
        • West China Hospital Sichuan University
      • Chongqing, Čína, 400030
        • Nábor
        • Chongqing University Cancer Hospital
      • Guangzhou, Čína, 510120
        • Nábor
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Čína, 510060
        • Nábor
        • Sun Yat Sen University Cancer Center
      • Hangzhou, Čína, 310009
        • Nábor
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanjing, Čína, 210009
        • Nábor
        • Nanjing Drum Tower Hospital
      • Shanghai, Čína, 200080
        • Nábor
        • Shanghai General Hospital
      • Shanghai, Čína, 200031
        • Nábor
        • Huashan Hospital Fudan University
      • Shanghai, Čína, 200082
        • Nábor
        • Xinhua hospital,Shanghai Jiaotong University
      • Tianjin, Čína, 300211
        • Nábor
        • The Second Hospital Of Tianjin Medical University
      • Wuhan, Čína, 430014
        • Nábor
        • The Central Hospital of Wuhan
      • Xi'an, Čína, 710061
        • Nábor
        • The First Affiliated Hospital of Xian Jiaotong University
      • Badalona, Španělsko, 08916
        • Nábor
        • Hosp. Univ. Germans Trias I Pujol
      • Madrid, Španělsko, 28034
        • Nábor
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Španělsko, 28041
        • Nábor
        • Hosp. Univ. 12 de Octubre
      • Murcia, Španělsko, 30008
        • Nábor
        • Hosp. Gral. Univ. J.M. Morales Meseguer
      • Seville, Španělsko, 41009
        • Nábor
        • Hosp. Virgen Macarena
      • Valencia, Španělsko, 46014
        • Nábor
        • Hosp. Gral. Univ. Valencia
      • Zaragoza, Španělsko, 50009
        • Nábor
        • Hosp. Clinico Univ. Lozano Blesa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion criteria:

  • Have histologically confirmed adenocarcinoma of the prostate
  • Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
  • Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
  • Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion criteria:

  • Known history of either brain or leptomeningeal prostate cancer metastases
  • Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
  • Prior or concurrent second malignancy (other than the disease under study)
  • Received cytotoxic chemotherapy for prostate cancer in any setting
  • Received prior treatment with human kallikrein 2 (KLK-2) directed therapies

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Pasritamig+Docetaxel

Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met.

Pasritamig will be administered.

Ostatní jména:
  • JNJ-78278343

Docetaxel will be administered.

Aktivní komparátor: Docetaxel

Participants will receive docetaxel along with prednisone/prednisolone as background medication.

Docetaxel will be administered.

Prednisone/Prednisolone will be administered.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Časové okno: Up to approximately 1 years 10 months

rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first.

Up to approximately 1 years 10 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Overall Survival (OS)
Časové okno: Up to approximately 4 years 5 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 4 years 5 months
Time to Symptomatic Progression (TSP)
Časové okno: Up to approximately 4 years 5 months

TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms.

Up to approximately 4 years 5 months
Time to Subsequent Therapy (TST)
Časové okno: Up to approximately 4 years 5 months

TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer

Up to approximately 4 years 5 months
Time to Skeletal-Related Event (TSRE)
Časové okno: Up to approximately 4 years 5 months

TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression.

Up to approximately 4 years 5 months
Objective Response Rate (ORR)
Časové okno: Up to approximately 4 years 5 months

ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR.

Up to approximately 4 years 5 months
Duration of Response (DOR)
Časové okno: Up to approximately 4 years 5 months

DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.

Up to approximately 4 years 5 months
Time to Prostate-Specific Antigen (PSA) Progression
Časové okno: Up to approximately 4 years 5 months

Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks

Up to approximately 4 years 5 months
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
Časové okno: Up to approximately 4 years 5 months

PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart.

Up to approximately 4 years 5 months
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
Časové okno: Up to approximately 4 years 5 months

PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart.

Up to approximately 4 years 5 months
Duration of PSA Response
Časové okno: Baseline and up to approximately 4 years 5 months

Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%.

Baseline and up to approximately 4 years 5 months
Progression Free Survival After Subsequent Therapy (PFS2)
Časové okno: Up to approximately 4 years 5 months

PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first.

Up to approximately 4 years 5 months
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
Časové okno: Up to approximately 4 years 5 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

Up to approximately 4 years 5 months
Number of Participants With Clinical Laboratory Abnormalities
Časové okno: Up to approximately 4 years 5 months

Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported.

Up to approximately 4 years 5 months
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Časové okno: Baseline up to approximately 4 years 5 months

The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
Časové okno: Baseline up to approximately 4 years 5 months

The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
Časové okno: Baseline up to approximately 4 years 5 months

The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning.

Baseline up to approximately 4 years 5 months
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
Časové okno: Baseline up to approximately 4 years 5 months

The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life.

Baseline up to approximately 4 years 5 months
Time to Sustained Worsening of Pain as Assessed by BPI-SF
Časové okno: Up to approximately 4 years 5 months

Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

Up to approximately 4 years 5 months
Treatment Side Effect as Assessed by EORTC IL46 Score
Časové okno: Up to approximately 4 years 5 months

The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".

Up to approximately 4 years 5 months
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
Časové okno: Up to approximately 4 years 5 months

The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life.

Up to approximately 4 years 5 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

19. prosince 2025

Primární dokončení (Odhadovaný)

19. listopadu 2027

Dokončení studie (Odhadovaný)

7. června 2030

Termíny zápisu do studia

První předloženo

6. listopadu 2025

První předloženo, které splnilo kritéria kontroly kvality

6. listopadu 2025

První zveřejněno (Aktuální)

10. listopadu 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit